Abstract
The S100A8/S100A9 heterodimer, commonly referred to as calprotectin (CP), is a member of the S100 subfamily of EF-hand calcium binding proteins that is largely expressed in activated monocytes and macrophages and has well-defined functions in acute and chronic inflammation. Indeed, certain S100 proteins including S100A8/A9 are exported from cells by an as-yet unknown mechanism. Once outside the cell, S100A8/A9 activates cell surface receptors such as the receptor for advanced glycation end products (RAGE) and has also been shown to inhibit the growth of pathogenic bacteria through the chelation of trace metal ions such as zinc (Zn2+) and manganese (Mn2+). The binding of these metal ions by S100A8/A9 has also been shown to induce apoptosis in various tumor cell lines. However, several lines of evidence have suggested that S100A8/A9-dependent apoptosis is not solely due to its ability to sequester Zn2+ from cells. Rather, it appears that trace metal binding to S100A8/A9 triggers a novel conformational switch in the protein, which promotes binding to specific sites on the surface of cells or through interaction with yet unidentified cell surface receptors. This review summarizes what is currently known regarding the molecular mechanisms by which S100A8/A9 performs its role as a novel apoptotic agent.
Keywords: S100A8/A9, calprotectin, apoptosis, zinc
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Volume: 8 Issue: 4
Author(s): Mohammad Hashemi, Seth Chitayat, Sudharsana Rao Ande and Walter J. Chazin
Affiliation:
Keywords: S100A8/A9, calprotectin, apoptosis, zinc
Abstract: The S100A8/S100A9 heterodimer, commonly referred to as calprotectin (CP), is a member of the S100 subfamily of EF-hand calcium binding proteins that is largely expressed in activated monocytes and macrophages and has well-defined functions in acute and chronic inflammation. Indeed, certain S100 proteins including S100A8/A9 are exported from cells by an as-yet unknown mechanism. Once outside the cell, S100A8/A9 activates cell surface receptors such as the receptor for advanced glycation end products (RAGE) and has also been shown to inhibit the growth of pathogenic bacteria through the chelation of trace metal ions such as zinc (Zn2+) and manganese (Mn2+). The binding of these metal ions by S100A8/A9 has also been shown to induce apoptosis in various tumor cell lines. However, several lines of evidence have suggested that S100A8/A9-dependent apoptosis is not solely due to its ability to sequester Zn2+ from cells. Rather, it appears that trace metal binding to S100A8/A9 triggers a novel conformational switch in the protein, which promotes binding to specific sites on the surface of cells or through interaction with yet unidentified cell surface receptors. This review summarizes what is currently known regarding the molecular mechanisms by which S100A8/A9 performs its role as a novel apoptotic agent.
Export Options
About this article
Cite this article as:
Hashemi Mohammad, Chitayat Seth, Ande Rao Sudharsana and Chazin J. Walter, Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8(4) . https://dx.doi.org/10.2174/187152309789838993
DOI https://dx.doi.org/10.2174/187152309789838993 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Current Drug Targets Increased Pulmonary Heme Oxygenase-1 and δ-Aminolevulinate Synthase Expression in Monocrotaline-Induced Pulmonary Hypertension
Current Neurovascular Research Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Review of Eugenol-based Nanomedicine: Recent Advancements
Current Bioactive Compounds Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Is the Vasculature a Potential Therapeutic Target in Arthritis?
Current Rheumatology Reviews Measuring Vasculitis with Numbers: Outcome Scores
Current Rheumatology Reviews Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry A Rare Case of Azathioprine-Induced Sweet`s Syndrome in a Patient with Crohn`s Disease
Current Drug Safety Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
Reviews on Recent Clinical Trials Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry